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Abstract
This paper assesses progress in the development of a global framework for responding to non-
communicable diseases, as reflected in the policies and initiatives of the World Health Organization
(WHO), World Bank and the UN: the institutions most capable of shaping a coherent global policy.
Responding to the global burden of chronic disease requires a strategic assessment of the global
processes that are likely to be most effective in generating commitment to policy change at country
level, and in influencing industry behaviour. WHO has adopted a legal process with tobacco (the
WHO Framework Convention on Tobacco Control), but a non-legal, advocacy-based approach with diet
and physical activity (the Global Strategy on Diet, Physical Activity and Health).
The paper assesses the merits of the Millennium Development Goals (MDGs) and the FCTC as
distinct global processes for advancing health development, before considering what lessons might
be learned for enhancing the implementation of the Global Strategy on Diet. While global
partnerships, economic incentives, and international legal instruments could each contribute to a
more effective global response to chronic diseases, the paper makes a special case for the
development of international legal standards in select areas of diet and nutrition, as a strategy for
ensuring that the health of future generations does not become dependent on corporate charity
and voluntary commitments. A broader frame of reference for lifestyle-related chronic diseases is
needed: one that draws together WHO's work in tobacco, nutrition and physical activity, and that
envisages selective use of international legal obligations, non-binding recommendations, advocacy
and policy advice as tools of choice for promoting different elements of the strategy.
Background
Since 1970, life expectancy at birth has improved steadily,
rising 7, 8 and 9 years, respectively, within high, middle
and low income countries to reach 79, 70 and 58 years, as
measured from data for the period 2000–2005 [1]. While
the underlying causes of these gains continue to be
debated [2], longer life expectancy has resulted in the glo-
bal predominance of non-communicable diseases as both
the leading cause of death, and of disease burden. Accord-
ing to World Health Organisation (WHO) estimates, non-
communicable diseases accounted for nearly 59% of the
57 million people who died in 2002 [3]. In the same year,
non-communicable diseases also outstripped both com-
municable diseases, and injuries, as the leading cause of
chronic illness worldwide, accounting for nearly 47% of
the 1.49 billion years of healthy life "lost" to illness, as
measured in DALYs [3].
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Within developing countries, this "epidemiological tran-
sition" reflects the higher proportion of adults in the pop-
ulation (due to declines in both fertility rates and infant
mortality) who, over time, age and become ill from dis-
eases that disproportionately affect adults [4]. In addition,
it reflects the rapid rise in behavioural risk factors includ-
ing smoking and high-sugar, high-fat diets. The "nutrition
transition" towards diets that are richer in saturated fats
and poorer in complex carbohydrates and dietary fibre,
fruit and vegetables; the growth of urban lifestyles involv-
ing less physical exertion; and the promotion and rising
consumption of tobacco and alcohol, have set the scene
for "lifestyle epidemics" to become the greatest health
challenge of the twenty-first century [5-9].
While the proximate behavioural risk factors for non-
communicable diseases are well-known, the underlying
environmental causes are both complex and global in
scale [10,11]. Environmental factors underlying the nutri-
tion transition include the industrialization of food pro-
duction, the growth of sophisticated supply chain
management on a global scale, the expansion of market
economies in developing countries, the growing concen-
tration of global food manufacturers as a result of mergers
and acquisitions, and the rapid growth of supermarkets in
the developing world. Rising incomes, price differentials
favouring the cheap production of energy-dense foods,
growing urbanization and rapid growth in demand for
pre-prepared foods, are also key factors [12-16]. While
"no food manufacturer commands a substantial share of
total world processed food sales", focused growth has nev-
ertheless created "concentrated markets...at specific prod-
uct and country levels" [17]. In 2002, over seventy-seven
percent of global food sales were of processed foods and
beverages [18]. To that extent, processed food manufac-
turers exercise a significant influence over global nutri-
tion. Market concentration is even more evident in the
tobacco market, where global cigarette production is
dominated by a small number of British, American and
Japanese corporations which have benefited from trade
liberalization and are pursuing growth in developing
countries [19].
This paper assesses progress in the development of a glo-
bal response to non-communicable diseases, as evidenced
by initiatives and policies of the World Health Organisa-
tion (WHO), World Bank and the UN: the institutions
most capable of shaping a coherent global policy.
Responding to the global burden of chronic disease
requires a strategic assessment of the global processes that
are likely to be most effective in encouraging the imple-
mentation of effective policies at country level, and in
influencing industry behaviour. Possible processes for
driving policy change, as illustrated in different global ini-
tiatives, include: (i) international legal instruments creat-
ing legal obligations on signatories to implement certain
policies; (ii) economic incentives; and (iii) partnerships
between global and national stakeholders for the
advancement of shared policy objectives.
A feature of both diet and tobacco-related diseases is the
presence of powerful multinational corporations and the
challenge of regulating their products. WHO has adopted
a treaty-based approach with tobacco [20], but a facilita-
tive, advocacy-based approach for diet and physical activ-
ity [21]. While the rapid entry into force of the WHO
Framework Convention on Tobacco Control (FCTC) has
focused global attention around this problem and
enhanced WHO's standing, the challenge of implement-
ing the FCTC and developing effective partnerships to
resist the influence of the tobacco industry at the country
level, is ongoing. WHO's Global Strategy on Diet, Physical
Activity and Health (GSDPAH), anticipates a broad coali-
tion of agencies and stakeholders working with countries
and the food industry towards implementation, but to
date, progress has been patchy [22,23].
This paper argues that global and national partnerships,
economic incentives, and international legal instruments
could each contribute to a more effective global response
to chronic diseases. While the FCTC may not be the
appropriate model for diet and obesity, the paper makes a
special case for the development of binding international
standards in select areas of diet and nutrition. At present,
the conceptual framework for global action on "lifestyle-
related" chronic diseases is largely embodied in two WHO
initiatives: the FCTC and GSDPAH. A broader frame of
reference is needed: one that links together WHO's work
in tobacco, nutrition and physical activity, and even alco-
hol, and that envisages the strategic use of international
legal standards, non-binding international recommenda-
tions, advocacy and policy advice as tools of choice for
promoting different elements of the strategy.
The impact of non-communicable diseases in 
developing countries
An impressive body of evidence supports the case for
urgent action in response to the growing burden of
chronic disease in developing countries [15,24-29]. The
epidemiological transition from communicable to non-
communicable diseases is far from uniform or complete,
especially in sub-Saharan Africa. Over the period 1990–
2001, the share of global deaths from HIV/AIDS grew
from 2% to 14% [25], reducing life expectancy at birth to
less than 40 years in several sub-Saharan African countries
[3]. Mortality in children less than 5 years has declined in
all regions since 1990, yet it still accounted for nearly 20%
of all deaths in 2001 [25]. Of these 10.5 million deaths,
nearly all were in low and middle income countries: diar-Globalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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rhoeal diseases, lower respiratory tract infections and
malaria were among the leading causes [3].
Heart disease, stroke, and chronic obstructive pulmonary
disease are now adding a "double burden" on low and
middle income countries, with epidemics of diabetes and
lung cancer reflecting rising rates of smoking and obesity.
In numerical terms, heart disease kills 17 million people
per year, in comparison to three million deaths from AIDS
[26]. In 2001, heart disease and stroke were the leading
cause of death in both high income, and low-middle
income countries, accounting for 27% and 21%, respec-
tively, of total deaths in each group [25]. However, due to
their larger populations, nearly 83% of these deaths
occurred in developing countries [25]. Evidence suggests
that illness and death from cardiovascular disease in
developing countries occurs at a younger age, cutting into
the productive years and undermining the benefits of the
lower dependency rate enjoyed by developing countries
with younger populations [3,26]. With more than 1.1 bil-
lion adults overweight worldwide, and 312 million of
them obese [30], diabetes is expected to double from 171
million to 366 million cases over the period 2000–2030.
Developing countries will have far higher numbers overall
(especially India, China, Southeast Asia and the Western
Pacific), with incidence peaking in the 45–64 age group
[31]. Overall, some 80% of DALYs from chronic diseases
fall on populations less than 60 years of age [28].
In 2000, tobacco caused an estimated 4.83 million prema-
ture deaths, 12% of total global mortality in those 30
years and above [32]. Half of these deaths were in the
developing world. More than 1 billion of the world's 1.3
billion smokers living in developing countries; as a result,
the future epidemic of tobacco-related diseases will
impact overwhelmingly on the developing world [33].
While total cigarette consumption has been decreasingly
sharply in the developed world since 1975, it continues to
rise in developing countries, largely due to population
growth [33]. Even assuming that tobacco control efforts
are successful in reducing smoking prevalence by 1% each
year in every country from 2003, there will still be over 1.3
billion smokers in 2010, and 1.45 billion in 2025 [33].
Overall, between one-half and two-thirds of long-term
smokers will die from tobacco-related diseases [34]. Peto
and Lopez estimate that if current patterns persist, tobacco
will kill about ten million people per year by 2030 (by
which time seven out of ten deaths will occur in develop-
ing countries), with 150 million deaths to 2025, and up
to 300 million from 2025–2050 [35].
Where do global processes fit within global 
health policy?
Lee, Fustukian and Buse provide a helpful framework for
disentangling four dimensions of global health policy-
making [36]. The first component is the policy actors: who
exercises sufficient (political) power to drive policy and to
influence decision-making at the global level? In the area
of non-communicable diseases, the United Nations,
WHO, the Food and Agricultural Organisation (FAO), the
World Bank, the World Trade Organisation (WTO), and
the Codex Alimentarius Commission, deserve particular
attention. Secondly, what are the processes through which
policy is developed, and implemented? What kinds of
interactions and relationships between policy actors are
most effective in leading to global health improvements?
The third component is the context of global policy devel-
opment. The pervasive theme here is globalisation itself: a
process reflected in the disappearance of boundaries, the
increasing integration of the global economy, and flowing
from that, the intensification of transnational interactions
and influences across physical, political, social and cul-
tural borders [37]. The point is often made that globaliza-
tion has diminished the capacity of countries to deal
effectively with major health threats occurring within
their borders, creating new imperatives for international
cooperation, and thrusting new responsibilities onto glo-
bal actors, civil society and the private sector [38-40]. Glo-
balization creates, in other words, new process challenges to
an effective response to national health problems. Coor-
dinated strategies involving partnerships between interna-
tional agencies, the private sector and nongovernmental
organizations (NGOs) are required because few policy
actors – global or not – are capable of single-handedly
driving policies across multiple sectors at country level in
order to lay the groundwork for population-wide health
improvements.
The specific things that policy actors seek to achieve
through these global activities and collaborations com-
prise the fourth component: the content of global health
policy. With non-communicable diseases, there is broad
recognition that effective strategies should address univer-
sal prevention at the population level, selective (or pri-
mary) prevention directed at high-risk groups, and
targeted (or secondary) prevention, and treatment, for
those with existing conditions [10]. Typically, policy pre-
scriptions for prevention direct attention to the key deter-
minants for the diseases in question and to the priority
settings for intervention. These determinants include glo-
bal factors and processes (as influenced by global policy
actors), socioeconomic factors and aspects of the political,
social and physical environment at country level, individ-
ual "lifestyles" and behaviours, access to health services,
as well as the design and functioning of national health
systems. Effective regulation of the structural and environ-
mental determinants of non-communicable diseases
requires interventions that extend well beyond the health
sector [41]. Policy influence is required in areas includingGlobalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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agriculture, finance and taxation, education, recreation
and sports, media and communication, transportation,
and urban planning [21]. Coordinating mechanisms are
needed to facilitate inter-sectoral and interdepartmental
cooperation [21].
This paper focuses not on the content of policies for non-
communicable diseases, but on the global processes best
suited to achieving enduring policy change at country
level, and to reducing long-term harm from industry prac-
tices. One available process is international law. Multilat-
eral agreements include "hard law" conventions that
contain legally-binding obligations, such as the WHO
Framework Convention on Tobacco Control (FCTC) [20].
They also include "soft law" resolutions and declarations,
such as the General Assembly's United Nations Millennium
Declaration  [42], which, although intended to create a
good faith obligation on member states to work towards
the MDGs, remains a recommendation with normative
effect only [43]. Global agencies can also develop guide-
lines, strategy documents and policy frameworks to assist
member countries: WHO's Global Strategy on Diet, Physical
Activity and Health (GSDPAH) falls into this category [21].
Discussion of the capacity for multilateral processes to
advance global health goals raises debate over the extent
to which global agencies, such as WHO, merely provide a
framework for members to express and pursue their inter-
ests, or whether they retain an independent capacity to
influence global policy in their own right [44,45]. The
development of global norms and strategies is an
intensely political process, as the FCTC and GSDPAH
illustrate [46,47]. In WHO's case, the better view may be
that the secretariat, executive board and World Health
Assembly (WHA) each operate in a fluid political environ-
ment that provides possibilities for, as well as real-world
constraints upon, innovation and leadership. Early reso-
lutions supporting the development of the FCTC, for
example, were supported by the WHO executive board
and adopted by the WHA, but over the opposition of the
secretariat [48]. Little progress was made, however, until
former Director-General Gro Harlem Brundtland took
office in 1998, making tobacco control a top priority,
establishing the Tobacco Free Initiative within her cabi-
net, and reviving the earlier (1996) mandate to begin mul-
tilateral negotiations for a framework convention [49,50].
What place for non-communicable diseases on 
the health development agenda?
The process of globalization has dramatically expanded
the scale of international cooperation and led to wide
array of binding and non-binding international instru-
ments that contribute to the protection of public health
[51]. This makes generalizations difficult. The central role
of health in economic development was boosted by the
World Bank's World Development Report 1993 [52], and
given further impetus by the signing of the Millennium
Development Declaration in 2000 [42,53]. A variety of
instruments – from conventions on hazardous chemicals,
to International Labour Organisation (ILO) conventions
on occupational health and safety, to various codes and
provisions on infant nutrition – answer to concerns about
non-communicable disease [51]. Despite this, the atten-
tion that "lifestyle-related", non-communicable diseases
have received, both in health development and in interna-
tional law, is grossly disproportionate to the share of glo-
bal death and disability that they represent.
The most significant health development program within
the United Nations system is the Millennium Develop-
ment Goals (MDGs). Health is a focus of three of the eight
goals ("reduce child mortality"; "improve maternal
health"; "combat HIV/AIDS, malaria and other diseases"),
and improvements in health would also advance those
goals relating to the eradication of extreme poverty and
hunger, education, and gender equality [54]. WHO points
out that "the health priorities reflected in the MDGs –
HIV, malaria, TB and other communicable diseases along
with maternal deaths – together account for 32% of global
mortality" [54]. While health is clearly central, therefore,
to the UN development agenda, non-communicable dis-
eases are conspicuously absent from the MDGs.
WHO's involvement in non-communicable diseases is
relatively recent and spans both legal and non-legal proc-
esses. WHO has a broad treaty-making power with respect
to matters within its competence, and regulations made
by the World Health Assembly bind Members on an opt-
out basis [55]. For most of its history, however, WHO has
focused on the provision of expert policy advice to gov-
ernments and neglected to use its law-making powers
[56,57]. As noted above, this changed in 1998 when –
under the leadership of its Director-General – WHO prior-
itized tobacco control and began negotiations towards a
framework convention. The FCTC was endorsed by the
World Health Assembly on 21 May 2003 and entered into
force on 27 February 2005 [20,58]. It currently has 146
signatories.
In January 2000, WHO established a Commission on
Macroeconomics and Health to inquire into the role of
health in global economic development. The Commis-
sion's report focused substantially on investment in
maternal and perinatal health, communicable diseases
and tobacco-related diseases [59]. The Commission's key
recommendations related to financing the scaling up of
access to essential health services, and to improved access
to medicines for the communicable diseases that dispro-
portionately burden poorer countries [59]. The Commis-
sion's focus on the Millennium health goals, plus tobacco,Globalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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gives implicit support to the view that communicable dis-
eases matter more to the poor than non-communicable
ones, and that the significance of non-communicable
conditions only increases as poverty recedes [[60], cf.
[61]]. This might be true of sub-Saharan Africa, but it is
not true of countries such as Russia, where life expectancy
is falling and the population is shrinking due to the cata-
strophic impact of cardiovascular disease, cancer, and
injuries [62]. Reducing the impact of cardiovascular dis-
ease, injuries and violence in Russia to EU levels would
improve life expectancy by over 10 years, as compared to
a gain of 0.88 years for reducing infant, child and mater-
nal mortality to EU levels [63].
Apart from the FCTC, WHO's main contribution in the
area of chronic, lifestyle-related diseases is its Global Strat-
egy on Diet, Physical Activity and Health (GSDPAH) (2004)
[21,64]. The GSDPAH adopts a facilitative, advocacy-
based approach. It builds on a brief, earlier strategy that
called attention to the role of tobacco, unhealthy diet and
physical inactivity in the most prominent non-communi-
cable diseases: cardiovascular disease, cancer, chronic
obstructive pulmonary disease and diabetes [65,66]. The
GSDPAH synthesises evidence for action and sets out the
key elements of a policy framework. It identifies the assist-
ance WHO is able to provide, together with the roles of
member states in implementing national policies, and the
respective contributions of other global policy actors, civil
society, and the private sector. Governments have a broad
role that encompasses coordination of policy across vari-
ous sectors and ministries; the provision of accurate infor-
mation and regulation of marketing, labeling, and health
claims; fiscal and agricultural policies; and promotion of
physical activity. The Global Strategy envisages close coop-
eration with other UN agencies, the WTO, World Bank,
other development banks and the Codex Alimentarius
Commission [21].
In May 2006, progress towards implementing the Global
Strategy was described as "limited by resource constraints,
both human and financial" [22]. By January 2007, twenty-
five countries had implemented (certain) policy options
recommended by the Strategy, and 17 were planning to
do so [23]. This disappointing assessment reflects "contin-
uing low investment in prevention and control of chronic,
noncommunicable diseases at local and global level"
[22]. In Europe, progress on non-communicable diseases
has been assisted by the recent adoption, by EU Ministers,
of a European Charter on Counteracting Obesity [67]. The
Charter  was drafted by the WHO Regional Office for
Europe and provides guiding principles and a policy
framework for EU countries. It calls for "visible progress"
within the next 4–5 years, and a reverse in rates of obesity
among children and adolescents by 2015 [67].
The World Bank remains one of the largest multilateral
investors in the health sector, committing US$13.9 billion
to Health, Nutrition and Population (HNP) projects
between 1997–2006, roughly split between Bank lending
and concessional IDA assistance [68]. The Bank's involve-
ment in health has developed over time and remains con-
troversial [69,70], partly due to its pursuit of "Washington
consensus" policies during the 1990s [71-73]. Since 1999,
the World Bank and International Monetary Fund (IMF)
have both sought to elicit greater political commitment,
stakeholder participation and country ownership of
development strategies by requiring all countries seeking
debt relief or concessional assistance to prepare Poverty
Reduction Strategy Papers (PRSPs) that identify develop-
ment goals and the policies, programs and resources
needed to achieve them [74,75].
The Bank enjoys several advantages as a global health pol-
icy actor. These include its global experience, strong coun-
try presence, capacity to engage with all government
sectors including Finance Ministries, and its capacity for
large-scale program implementation including financing
and financial management [68]. This gives the Bank a
unique capacity to engage with the determinants of non-
communicable disease from a system-wide perspective
within client countries. Under the 1997 HNP strategy, the
Bank has focused on health systems development, health
care financing, and improving the health, nutrition and
population outcomes of the world's poor [76]. In practice,
priority in lending and policy dialogue has gone to achiev-
ing the MDGs [77]. Work towards the 2007 HNP strategy
does not suggest any major departure from this approach,
although the Bank acknowledges that non-communicable
diseases have become a "critical challenge" due to "an epi-
demic of obesity and tobacco consumption" in most mid-
dle income and many lower income countries [68]. Given
the proliferation of entities financing single diseases and
vaccines, the Bank has signaled a greater focus on
strengthening health systems as a whole as a way of
achieving its other health objectives [68]. This strategic
focus is important: to be capable of responding effectively
to chronic diseases, health systems must be capable of
providing continuity of care in the community, with serv-
ices encompassing primary and secondary prevention,
monitoring of risk factors and treatment of chronic illness
[41,78].
In summary, communicable diseases and the MDGs
remain the priority of the leading global agencies invest-
ing in health. The FCTC has improved the visibility of
tobacco as the world's leading cause of preventable dis-
ease, but obesity, diet and physical activity are yet to
achieve priority status, despite growing policy interest in
obesity in developed countries. Over the past decade, pri-
vate foundations and public/private partnerships haveGlobalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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injected significant new funding into the health sector.
This has mostly been directed to priority communicable
diseases (HIV/AIDS, malaria, TB) or to other vertical pro-
grams (vaccinations, essential medicines), rather than to
chronic diseases initiatives [68,79]. Despite the much-
touted role of civil society and the private sector in global
health governance, their capacity to refocus and coordi-
nate global health strategies should not be over-stated.
Global health agencies need to be centrally involved with
chronic diseases, providing "institutional focal points for
global debate", political mobilization, and law-making
[40].
What can we learn from the Millennium 
Development Goals and the Framework 
Convention on Tobacco Control?             
The Millennium Development Goals (MDGs) and the
Framework Convention on Tobacco Control (FCTC)
reflect two different processes for advancing global health
policies. The FCTC is an evidence-based treaty that identi-
fies core areas of consensus over regulatory measures that
signatory countries are legally required to implement
within their domestic systems. The MDGs are a global
partnership embracing ambitious goals to be achieved
collectively within a 15 year timeframe (2000–2015). In
addition to legal obligations, and partnerships involving
global and national stakeholders, economic pressure and
funding conditionality – historically associated with
World Bank lending – provide a third process for encour-
aging policy change at country level.
A global political partnership: the Millennium 
Development Goals
The remarkable achievement of the Millennium Declara-
tion was to "re-package" key global challenges into a sin-
gle cluster of political commitments, while delivering the
crucial coordinating role to the Secretary-General to trans-
late the commitments into a coherent work program, and
to report periodically to the General Assembly [42,80].
From the beginning, work on the MDGs has sought to
strengthen linkages with a wide range of stakeholders,
including other international agencies within and beyond
the UN system [81]. By locating the executive functions
directly within the UN Secretariat, the MDGs found a high
profile "political champion" and became the preeminent
development priority within the United Nations system.
This political impetus has been significantly strengthened
by the commitment, technical expertise and/or financial
backing of partner institutions, including WHO and the
World Bank.
This is not to deny that there have been setbacks in
progress towards the MDGs. While financial and human
resource constraints are a factor, effective interventions
need to be better targeted to the poor, policies need to
focus on prevention and demand for health care at the
household level, and health systems need strengthening
overall [82]. No process can guarantee success. The scale
of the challenge, however, demonstrates the need for a
partnership approach. Provided there is sufficiently close
alignment between "partnership aims" and the core func-
tions of each agency, partnerships multiply the resources
available for furthering partnership goals, and the oppor-
tunities for policy influence at country level. While the
"MDGs do not reflect the entirety of WHO's work", they
are "central to its agenda...and represent important mile-
stones against which the Organization's overall contribu-
tion to health development can be measured" [54].
Similarly, although World Bank activities extend well
beyond health, there is a natural fit between " [t]he first
seven Millennium Development goals" and "the activities
of the health, nutrition and population sector in the
World Bank, either as health and nutrition status indica-
tors or as determinants of health outcomes" [83].
Binding global norms: The Framework Convention on 
Tobacco Control
The success of multinational tobacco corporations in pen-
etrating developing country markets due to mergers and
trade liberalization, and the resulting globalization of the
tobacco epidemic, have galvanized support for the devel-
opment of global norms for tobacco control. Interna-
tional legal agreements have been recognised as "global
public goods" that strengthen national capacity to achieve
public health goals by adopting a unified response to tran-
snational threats [19,84]. International law has a direct
impact on domestic laws and policies because of the obli-
gation that countries accept, upon ratification of a treaty,
to implement its provisions. The intention behind the
FCTC is that parties to the treaty will regulate their domes-
tic tobacco economies and impose legal constraints on the
activities of tobacco manufacturers and retailers.
The FCTC reflects a framework-protocol approach. It sets
out "baseline international norms", together with institu-
tional arrangements for global governance of tobacco:
provisions relating to a permanent Secretariat and peri-
odic conference of the parties, the exchange of informa-
tion, reporting and technical cooperation, and the
financing of Convention objectives. The framework-pro-
tocol approach was a strategic choice made in the light of
concerns about loss of sovereignty and trade, pressure
from the tobacco industry, and the evolving evidence base
about harm from exposure to tobacco [19,20,48,85]. The
later development of protocols provides scope for the
deepening of international standards as political will
hardens in response to the success of tobacco control pol-
icies, reduced smoking prevalence, and waning industry
influence [86]. A feature of the FCTC was the participation
of NGOs during the negotiations and their ongoing inputGlobalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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into the conference of parties [87,88]. The FCTC also pro-
vides a mandate for the development of global standards
for regulating the constituents of tobacco products. This is
a novel feature of the Convention that adds harm reduc-
tion measures to the more traditional supply and demand
controls [20].
As a convention negotiated in the shadow of tobacco
trade liberalization and industry influence, the evidence
base for tobacco control was critical to the political legiti-
macy of the FCTC process. This will remain the case in
future, whenever global health standards challenge eco-
nomic and business interests. Public health advocates are
divided over the potential for World Trade Organisation
(WTO) agreements to undermine the capacity of national
governments to protect public health [89-92]. The FCTC
provides a mandate for domestic tobacco control legisla-
tion through a global treaty negotiated outside the WTO
process. It makes better sense for WHO to act assertively
as a global policy actor in its own right and to coordinate
the development of new legal standards in a forum
"where public health issues predominate", than to seek to
carve out new exemptions for health from the WTO [89].
The WTO is neither a scientific nor a health agency and it
does not develop standards [93]. The shaping of global
health standards is therefore best achieved through WTO
input into WHO processes, rather than the other way
around. The recent WTO Panel Report in the EC-Biotech
Products case suggests that WTO disputes are likely to be
resolved on narrow terms, with little regard to other inter-
national obligations not assumed by all disputing parties
(if not all WTO members) [94]. As discussed below, the
development of global health standards, in a manner con-
sistent with WTO obligations, provides the best protec-
tion for countries who wish to avoid the threat of trade
disputes arising from their domestic public health poli-
cies.
The FCTC has brought considerable prestige to WHO. At
the same time, the FCTC process lacks the "shared owner-
ship" of global policy goals that characterizes the UN/
WHO/World Bank response to the MDGs. The mutually
reinforcing influences made possible through partner-
ships could significantly assist an agency such as WHO,
which has limited resources of its own, and whose politi-
cal influence is centred on Health Ministries. In this
respect, New York Mayor Michael Bloomberg's historic
donation of $125 million towards tobacco control efforts
in low and middle income countries, provides interesting
opportunities for new partnerships to evolve in tobacco
control [95].
WTO rules and international health standards
As the FCTC illustrates, one important way of minimizing
the scope for conflict between global health goals and
trade obligations is to develop international health standards.
Under the General Agreement on Tariffs and Trade (GATT),
WTO members are required not to adopt measures that
discriminate between the imports of different countries,
or between domestic goods and imports. These are the
"Most Favoured Nation" rule, and the "National Treat-
ment" rule in GATT Articles I, and III, respectively [91,96].
GATT contains an exception to these rules for measures
"necessary to protect human, animal or plant life or
health" (Art XX(b)) [96].
The scope of the exception is clarified by the WTO Agree-
ment on the Application of Sanitary and Phytosanitary Meas-
ures (SPS Agreement). The SPS Agreement applies to "SPS
measures", including domestic laws or policies applied to
protect human life and health from additives, contami-
nants, toxins or disease-causing organisms in foods and
beverages. Where they exist, the SPS Agreement requires
members to base their SPS measures on international
standards, guidelines or recommendations [97]. Member
states whose SPS measures conform to international
standards are deemed to be acting consistently with both
the SPS Agreement itself, and GATT Article XX(b). Mem-
ber states whose SPS measures exceed the requirements of
international standards, however, must demonstrate that
those standards are supported by and do not exceed the
scientific evidence, and are based on an assessment of the
risks to human life or health [97].
The WTO Agreement on Technical Barriers to Trade (the TBT
Agreement) applies to technical regulatory measures that
are not covered by the SPS Agreement [98]. Under the TBT
Agreement, member states must comply with the "Most
Favoured Nation" and "National Treatment" rules. They
must also ensure that technical regulations do not create
"unnecessary obstacles to international trade", by being
"more trade-restrictive than necessary to fulfil a legitimate
objective". Where they exist, member states must base
their domestic standards on international standards, and
when applied for a legitimate objective, such standards
will be "rebuttably presumed not to create an unnecessary
obstacle to international trade" [98]. The legitimate objec-
tives include preventing deceptive practices, and the pro-
tection of human health or safety [98]. Although the SPS
and TBT Agreements can not apply to the same measure,
the WTO Panel report in the EC-Biotech Products case sug-
gests that specific requirements embodied in a domestic
law (in this case an EU law) can themselves be considered
to embody both an SPS and a TBT measure, depending on
the purpose for which they are applied [94]. This suggests
that domestic laws enacted in accordance with TBT provi-
sions might withstand scrutiny even if they failed as SPS
measures.Globalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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The "human health" exceptions in WTO rules provide a
space for the development of global health norms as a
way of overcoming "regulatory chill": the reluctance of
governments to introduce domestic public health laws for
fear of inviting trade disputes. Indeed, the development of
evidence-based international standards perform a valua-
ble function. As noted above, domestic laws based on
international standards are deemed to satisfy SPS obliga-
tions and will presumptively satisfy TBT obligations. Fur-
thermore, when member states introduce SPS measures in
the absence of international standards, or where those
measures go beyond international standards, they bear
the onus of demonstrating that each measure is reasona-
bly supported by a risk assessment as defined in the Agree-
ment [97]. Countries seeking to protect the health of their
populations are therefore well served by global agencies
that are actively engaged in standards development.
Leveraging the Global Strategy on Diet, Physical 
Activity and Health
The Millennium Development Goals and the Framework
Convention on Tobacco Control serve as helpful models
when considering ways of strengthening the global
response to non-communicable diseases.
Global targets for reductions in chronic diseases?
At first glance, WHO's Global Strategy on Diet, Physical
Activity and Health (GSDPAH) shares similarities with the
MDG process. WHO is the obvious "political champion"
for the strategy, which proposes: "an ad hoc committee of
partners within the United Nations system", as well as
links with NGOs and the private sector [21].
The MDG model suggests that the challenge for WHO, if
adopting a partnership approach to the GSDPAH, is to
successfully link implementation to the core functions –
and resources – of partner agencies. One way to achieve this
is to integrate non-communicable diseases into an exist-
ing global health partnership. Commentators have sug-
gested that the MDGs should expand to include non-
communicable disease targets. There have been calls to
broaden the child mortality focus of the MDGs to include
adult mortality and morbidity, either as a separate goal in
its own right, or as a target falling under Goal 6, which
aims to "combat HIV/AIDS, malaria and other diseases"
[29,63,99]. The contribution that tobacco control policies
can make to the MDGs has been emphasized [54,100],
and commentators have also stressed the link between
chronic diseases and poverty reduction [101].
The Millennium Development Goals have achieved broad
acceptance as a framework for measuring and achieving
social development. This may be reason enough for cau-
tion in tinkering with them, or seeking to re-cast them
mid-stream. An additional set of UN-sponsored health
targets could undermine the status the MDGs have man-
aged to achieve as global priorities and aggravate existing
difficulties in progress towards them [54,82,102,103].
The UN Secretariat is fully invested in the MDGs and
unlikely to take on new responsibilities around chronic
diseases.
This has not stopped public health advocates, and WHO
itself, from advocating a global goal of reducing death
rates from chronic diseases by 2% annually, resulting in
36 million fewer deaths by 2015 [27,29]. The difficulty is
that goals are ends, rather than means [102]. To achieve
global goals requires the simultaneous action of many
countries: each making budgetary commitments, imple-
menting policy changes, and monitoring outcomes in
order to achieve real results on the ground.
The importance of linking global goals to legal, economic,
or multilateral political processes can be illustrated by
contrasting WHO's Commission on Macroeconomics and
Health with World Bank concessional (IDA) credits. In its
2001 report, the Commission recommended the estab-
lishment of national commissions to lead the process of
scaling up access to essential health services [59]. This
process has also been identified as providing the opportu-
nity to include strategies for cardiovascular disease [100],
and to adapt MDG targets to the health priorities of indi-
vidual countries [104]. By 2006, only 20 countries had
established national commissions or used existing bodies
to strengthen health policy reform [104].
For World Bank borrowers, the Poverty Reduction Strategy
Paper (PRSP) process requires countries seeking conces-
sional financing to identify their national development
priorities in a PRSP. The Bank and the IMF exercise con-
siderable real-world influence over these country-level
priorities. In a recent review, both agencies echoed a call
by the UN Development Program to use the PRSP process
as a vehicle for scaling up country-level efforts to achieve
the MDGs [53,74,75]. The PRSP process could also pro-
vide an operational framework for setting out the strate-
gies required to meet national goals on non-
communicable diseases. The advantage of the PRPS proc-
ess is the economic incentive it creates to take concrete
actions in support of national priorities.
Appropriate global partners?
The advantages of a partnership approach to global health
challenges include greater access to expert input and advo-
cacy from policy partners, greater publicity for policy
goals, and greater opportunity for engaging at country
level beyond traditional WHO-Health Ministry relation-
ships. The GSDPAH identifies a wide range of potential
partners including ECOSOC, the ILO, UNESCO, and the
WTO. There are some clear synergies; for example, withGlobalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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the Food and Agricultural Organisation (FAO) around
promoting the supply and consumption of fruit and veg-
etables [105], and with UNICEF, around children's diets,
nutrition education, and food marketing. Given its strong
human rights focus, UNICEF could be an important ally
in advocating a restrained approach to industry market-
ing, reprising the role if played during development of the
International Code of Marketing of Breast-Milk Substitutes
[106].
The Codex Alimentarius Commission, as the body
responsible for developing global food standards, has
been identified by WHO as an important partner in the
GSDPAH [21]. This partnership is significant since coun-
tries implementing Codex standards are presumed to be
acting consistently with GATT and the SPS Agreement
[96,97]. FAO/WHO have highlighted the role that the
Codex Committee on Food Labeling might play in develop-
ing guidelines on the use of consumer-friendly nutrition
labeling and health claims [107]. They have also pointed
to the role that the Codex Committee on Nutrition and Foods
for Special Dietary Uses could play in developing food com-
position standards [108]. Codex is awaiting a joint WHO/
FAO paper outlining concrete proposals that it might take
[109].
It is highly uncertain whether the involvement of Codex
will contribute to progressive global standards, given its
reputation for being dominated by industry [110,111].
Historically, Codex – like national food regulators – has
focused on food safety, rather than nutritional quality. On
one view, there is limited scope for WHO to address issues
falling within the Commission's authority, since conflict-
ing WHO/Codex standards could create confusion, and
might undermine WHO's position, given the status of
Codex standards under WTO rules [112]. However, this
criticism could also be made of WHO's marketing code
for Breast-Milk Substitutes [106]. Rather than risk aban-
doning important areas of diet and nutrition to Codex,
WHO could make a virtue out of Codex' technical and his-
torically more limited role, seeking Codex input while
nevertheless retaining ownership of the key areas of labe-
ling, health claims, and food composition standards for
trans and saturated fats, salt and free sugars. As with the
FCTC, there is strategic benefit in locating standards devel-
opment within a forum where health issues predominate.
As noted above, the World Bank could be an important
partner for implementing the GSDPAH, especially given
its greater financial resources. There are several areas
where the GSDPAH overlaps with World Bank invest-
ments in health, nutrition and population (HNP). The
first is in tobacco, where the Bank's work on the economic
benefits of tobacco control policies, including tobacco
taxes, complements WHO's desire to encourage imple-
mentation of the FCTC [113]. Secondly, the Bank has
staked out nutrition as a priority. The Bank acknowledges
that obesity is part of the nutrition policy agenda [114],
and diet-related interventions are a cost-effective way of
preventing cardiovascular disease [9,115]. As with
tobacco, it makes sense to pool WHO's technical and pol-
icy experience with the Bank's resources and country-level
knowledge wherever possible. Thirdly, the new HNP strat-
egy for the Bank makes public health surveillance and
health system performance monitoring a priority [68].
Besides permitting better evaluation of the Bank's own
programs, enhanced surveillance cannot but call attention
to the growing burden of chronic disease. Finally, as noted
above, the Bank could require concessional borrowers to
address non-communicable diseases within their Poverty
Reduction Strategy Papers.
While partnerships between international agencies prima-
rily enhance links with government, NGOs and civil soci-
ety networks have a broader role. Besides pressuring
governments to implement healthy policies, that role can
extend to pressuring the private sector for access to health-
ier foods, sharing information, and influencing consum-
ers directly in ways that reduce lifestyle risk factors and
shape market demand [116]. The GSDPAH expresses high
hopes for partnerships with civil society, NGOs and the
private sector, but their assistance in advancing the strat-
egy appears to be modest so far [22].
Are partnerships with the processed food industry a good 
idea?
In contrast to the tobacco industry, WHO has welcomed
the food industry as a partner, citing its capacity to
develop healthier products and to encourage healthier
choices [21,117]. This is a high-risk strategy, given well-
publicised attempts by the United States, acting on behalf
of its sugar industry, to weaken the GSDPAH during its
development [47,118]. In 2006, a study of global food
manufacturers, retailers and food service companies con-
cluded that only a minority had altered their business
practices in response to the GSDPAH. Of the 25 corpora-
tions studied, ten had taken action on salt, five on sugar,
four on fat and eight on trans fats, but only two on por-
tion sizes [119]. In Europe, the EU Platform for Action on
Diet, Physical Activity and Health has, since March 2005,
provided a forum for the food industry, as well as NGOs,
medical and consumer groups, to make public commit-
ments on measures to reduce obesity and to improve diet
and physical activity [120-122]. For example, nine soft
drink makers have undertaken not to advertise soft drinks
to children aged 11 or less, reaping high praise from the
European Health and Consumer Protection Commis-
sioner [123]. In the United States, the Alliance for a
Healthier Generation, a joint initiative of the American
Heart Association and the William J. Clinton Foundation,Globalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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has negotiated voluntary agreements with three large bev-
erage markers, and five large snack food makers, to com-
ply with new school beverage and competitive food
guidelines in their marketing to 123,000 schools nation-
wide [124-127].
If partnerships between global health agencies, govern-
ments, and the private sector yield tangible outcomes, so
much the better. Pursuing voluntary commitments is
cheaper and faster than the difficult process of standards-
setting. However, short-term gains should not be con-
fused with the trans-generational challenge of improving
global diets. At the population level, a reduction in the
burden of chronic disease requires reduced consumption
of high-sugar, high-fat, high-salt foods, and increased con-
sumption of fresh fruit and vegetables – in most countries
in the world.
The dilemma for the processed food industry is that
"'good' foods are bad commodities with low profit mar-
gins while 'bad' foods are good commodities with high
margins" [128]. It is difficult for consumer demand to
drive industry improvements when that demand is itself
skillfully manipulated by vast advertising expenditures
exceeding WHO's annual budget many times over [119].
It is perfectly rational for global food companies to coop-
erate to the degree necessary to enhance their reputations
and to avoid threats of regulation while nevertheless pro-
tecting established markets for energy-dense foods of poor
nutritional value.
Should there be global legal standards on diet and 
nutrition?
Leading public health advocates have shown little enthu-
siasm for using treaties to progress a global strategy on
diet, nutrition and physical inactivity [5,129,130],
although this view has been challenged [88,131,132].
WHO's preference for a voluntaristic approach may rest
on several assumptions: that partnering with industry is
the most effective way of aligning commercial incentives
with consumer health interests, that regulation will
destroy communication channels with business, and that
regulatory options are not politically feasible and could
backfire. WHO's reluctance may also reflect the fact that
the determinants of nutrition and obesity-related disease
are complex and cannot easily be reduced to legal princi-
ples, and perhaps that the evidence base for intervention
is less robust than in tobacco control.
Like tobacco, nutrition and obesity-related diseases
develop over a considerable period of time. Commenta-
tors point out, however, that unlike tobacco, food is not
hazardous per se, except when perished or adulterated
[133]. This distinction directs attention away from the
constituents of individual foods and beverages, towards
lifestyles and dietary choices. The food industry argues
that the solution lies with the individual (more physical
activity, wiser food choices), assisted by wider product
choice where consumer demand makes this commercially
viable. What cannot be denied is that if high-fat, high-salt,
high-sugar foods are "hazardous when consumed [too]
frequently" [133], then reducing the hazard means either
altering the products that are (over)consumed, thereby
potentially interfering with their market appeal, or inter-
vening with supply and demand in ways that reduce con-
sumption levels. Each one of these strategies: changing
product composition, influencing demand for, or regulat-
ing the availability of, food products, puts markets at risk.
Voluntary commitments by industry are welcome and
should be accepted whenever offered. But public health
stakeholders should be aware that business corporations
are not constituted to act sacrificially in pursuit of worthy
aims. "Forbearance" from pursuing certain kinds of sales
opportunities may prevent damage to – or even enhance
– a company's reputation. To that extent, investments in
corporate social responsibility can bring economic bene-
fits. As Redmond points out, business corporations may
engage in social and human rights entrepreneurialism,
competing for consumers or investors "by means of sig-
naled respect for human rights standards in company
operations" [134]. Corporations may also embrace volun-
tary codes and principles to forestall the risk of more
intrusive or costly forms of regulation in future [135].
Company executives may be well motivated and keen to
make the world a better place. But corporations have little
incentive to re-shape public tastes and existing product
lines, as distinct from offering marginally "better for you"
variants, when doing so risks sacrificing existing markets
and provides opportunities for competitors. Regulation
has the advantage of creating a level playing field; while
food companies may not like regulation, they understand
it and will usually absorb it into their operations as effi-
ciently as they can.
Clearly, not all aspects of diet, nutrition and physical
activity are appropriate subjects for legal standards, even
aspirational or broadly-stated ones. For example, physical
activity and food choices at the individual level are a mat-
ter for personal choice, except in schools. Food security,
and the provision of fresh fruit and vegetables at afforda-
ble prices, are more likely to be a matter for national pol-
icy and coordination across the agricultural, finance,
trade, employment, transport and health sectors, rather
than legal prescriptions. Strategies to encourage physical
activity and healthy eating may also, appropriately, vary
from country to country. There are four areas, however,
where the development of global standards could leverage
the Global Strategy beyond a purely voluntary menu of
policy options for governments.Globalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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The first area relates to the informational basis for making
informed and healthy food choices: standards for the
labeling of product constituents, fair warning of health
risks, and health claims. Accurate information in rapidly-
digestible formats could enhance competition for healthy
products. In so far as markets have failed to provide con-
sumers with sufficient information, or have perverse
incentives to obscure such knowledge, regulation may be
justified as a "public good" [136].
Domestic laws implementing global standards in this area
would need to be consistent with that country's WTO
obligations. As noted above, the WTO Panel report in the
EC-Biotech Products case suggests that a particular legal
requirement might be considered to embody both an SPS
and a TBT measure, although justification of the measure
under either Agreement will be sufficient [94]. To the
extent that national laws embodying or requiring compli-
ance with international standards on labeling were
enacted in order to inform consumers, or to avoid confu-
sion or misleading impressions, they would be "rebutta-
bly presumed not to create an unnecessary obstacle to
international trade", under the TBT Agreement [98].
In some cases, labeling requirements and health warnings
might also be characterized as intending to warn consum-
ers of the health risks of over-consumption of product
ingredients, such as salt, sugar or fat. The SPS Agreement
applies to measures that are intended to mitigate risks to
human life or health arising from "additives, contami-
nants, toxins or disease-causing organisms". In the EC-
Biotech Products case, the Panel distinguished between
foods that posed a danger to the life or health of the cus-
tomer, and foods that were nutritionally disadvantageous
due to the quality or quantity of their nutrients, but with-
out necessarily presenting a danger to the health of the
consumer. The Panel made it clear that the SPS Agreement
only applies to laws seeking to address a "danger for the
consumer" [94].
This approach supports the argument that laws seeking to
mitigate the risks of harmful diets by warning consumers
about the (poor) nutritional quality of a food, would not
be SPS measures, although they might well fall for consid-
eration under the TBT Agreement. It follows that the ques-
tion of whether salt, sugar or fat can be described as an
"additive" creating a risk to human health, within the
terms of the SPS Agreement, will not arise. In any event,
the Panel interpreted "food additive" to mean a substance
"not normally used as a typical ingredient" in food, which
would seem to exclude sugar, salt and fat [94]. It seems
likely that future WTO Panels would follow this interpre-
tation, since it avoids framing diet-related harms in terms
of the intrinsic properties of salt, sugar and fat in food, as
distinct from their nutritional impact over time. The end
result is that health warnings about the nutritional quality
of food are likely to be treated as TBT measures.
The second area for the development of international
standards relates to food composition. Estimates from the
Global Burden of Disease Study indicate that high blood
pressure, high cholesterol, and overweight and obesity,
respectively, were responsible for 46%, 24%, and 11% of
global mortality from cardiovascular disease in 2001, and
almost equivalent shares of CVD morbidity [137]. There
is an established relationship at the population level
between salt intake and blood pressure, and between die-
tary fats and cholesterol, blood pressure and weight [9].
Applying the distinction made by the Panel in the EC-Bio-
tech Products case, evidence-based regulations or recom-
mendations on food composition, based on dietary risks
to health at the population level would likely be treated as
TBT measures. National legislation implementing such
measures would bind multinational food corporations
and other food producers, and could improve dietary bal-
ance by reducing the intake of trans and saturated fats,
salt, and sugar, at the population level.
A third possible area for legal intervention relates to chil-
dren's health, nutrition and education and, more contro-
versially, food marketing to children. Despite the
reluctance of many governments to interfere with market
processes, there is wide acceptance that the vulnerability
of children supports protective regulation. WHO's Interna-
tional Code of Marketing of Breast-milk Substitutes already
bans promotion of breast-milk substitutes [106]. A recent
WHO-sponsored forum and technical meeting concluded
that self-regulation of food and beverage marketing
directed at children is unlikely to be effective, and recom-
mended that WHO develop an international code
addressing promotional activities by transnational com-
panies irrespective of country [138]. In so far as "the ori-
gins of obesity and NCDs such as cardio vascular heart
disease and diabetes...lie in early childhood", regulations
aimed at enhancing children's nutrition would be highly
cost-effective [114,139].
A fourth area for global standards relates to surveillance of
chronic disease risk factors and the obligation to report on
progress in implementing policies on non-communicable
diseases. Reporting provisions can help to maintain com-
mitment towards tackling longer-term problems and
enhance the implementation of both legal and non-legal
aspects of a global strategy. Periodic reporting also pro-
vides a focal point for the participation of civil society
[85].
One criticism of the GSDPAH and of WHO's framework
for implementation [140] is that it anticipates purely vol-
untary measures at a time when developed countries areGlobalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
Page 12 of 16
(page number not for citation purposes)
debating and experimenting with legal strategies to com-
bat obesity and chronic diseases in precisely the areas
identified above. For example, Denmark has outlawed the
use of trans fats in food [141]. New York City has banned
artificial trans fats in restaurant cooking [142,143], and
requires the provision of calorie information on restau-
rant menus [144]. The Food Safety Authority of Ireland is
negotiating salt commitments with food businesses [145],
while in the United States, public health bodies are lobby-
ing for the Food and Drug Administration (FDA) to regu-
late salt as a food additive [146-148]. Britain's
telecommunications regulator, Ofcom, has banned televi-
sion advertising of foods assessed as high in fat, salt or
sugar during children's programs [149,150]. Similarly, the
European Charter on Counteracting Obesity specifies that EU
governments should adopt specific regulatory measures to
"substantially reduce the extent and impact of commercial
promotion of energy-dense food and beverages" to chil-
dren, moving towards an international code of practice in
this area [67]. The United States is a social laboratory for
a variety of legal responses to obesity [151,152]. Congress
has imposed conditions on federal grants funding school
breakfast and lunch programs that require compliance
with nutrition guidelines and nutrition education within
the curriculum [153-155].
The use of law as a process for developing global stand-
ards for diet and nutrition needs to be distinguished from
the use of law as a process for implementing those stand-
ards at the domestic level (through legislation). Ulti-
mately, whether developed countries pass domestic laws
in the areas identified above, or secure the health of their
populations in other ways, is not the point. The point is
that global standards provide a baseline for responsible
transnational corporate behaviour. Appropriately imple-
mented at country level, binding international standards
on diet and nutrition will make the health of future gen-
erations less dependent upon corporate charity and vol-
untary commitments. It will also reduce the "regulatory
gap" that might otherwise emerge between developed and
developing countries, due to the vulnerability of the latter
to pressure from large transnational corporations.
If not a treaty on diet and nutrition, then what?
Regulatory approaches to diet and nutrition need not
imply the replication of the FCTC approach to the food
industry [130]. Any attempt to mirror the FCTF approach
by consolidating the regulation of food composition,
labeling, health claims, food advertising and children's
health and nutrition into a single instrument would likely
fail due to political divisions and industry opposition.
While progress on all these fronts is desirable, each ele-
ment also has value in itself. By keeping issues separate;
for example, by developing separate standards for salt,
fats, and sugar, labeling, and marketing, WHO could
more effectively maintain the focus on evidence in each
case, and limit engagement to those whose interests were
directly affected by the standards in each case. One hopes,
for example, that an instrument on salt would not be
thrown off course by lobbying for and on behalf of the
sugar industry. This multi-track approach need not, how-
ever, limit the influence of NGO and consumer groups.
Issues where the evidence is strongest should be tacked
first. All issues should be framed as components of a
broader global strategy on non-communicable diseases
comprising "hard law", "soft law", and purely recommen-
datory elements.
WHO has an unambiguous constitutional mandate to
"develop, establish and promote international standards
with respect to food, biological, pharmaceutical and sim-
ilar products" [55]. While WHO's treaty-making power is
expressed in general terms to extend to any matter within
its competence, its power to make regulations extends to
specific, enumerated areas [55,132]. WHO's regulations
power extends to making advertising and labeling stand-
ards, and standards with respect to the safety, of "biologi-
cal, pharmaceutical and similar products moving in
international trade" [55]. If "similar products" includes
food, then WHO's power to make regulations in these
areas seems assured; on balance, however, a narrower
interpretation seems likely. A more promising basis for
developing standards on diet and nutrition depends on
whether such standards come within the terms of: "sani-
tary and quarantine requirements and other procedures
designed to prevent the international spread of disease" (Article
21(a)). If "disease" is given a narrow meaning, to exclude
chronic, diet-related diseases, then WHO would be
required to either use its treaty power (Article 19), or to
make non-binding "recommendations" (Article 23). Ulti-
mately, the scope of Article 19 will depend on whether a
political consensus can be reached among World Health
Assembly members.
At the present time, it may seem novel to talk about
national and international laws for fighting heart disease,
diabetes and other chronic diseases. However, non-com-
municable diseases are highly unlikely to remain a "law-
free zone" over the medium term. Even assuming that no
consensus can be reached on the use of WHO's treaty or
regulations power, the development of recommendations
preserves the obligation of states to report to WHO peri-
odically (Article 62), and WHO could publicly state its
aspiration to consolidate recommendations in this area
into a legally binding instrument at a later date.
In summary, the opportunities for using international law
as a process for implementing the GSDPAH have been
underestimated. The transnational factors influencing die-
tary trends, and the degree of control that transnationalGlobalization and Health 2007, 3:2 http://www.globalizationandhealth.com/content/3/1/2
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corporations exercise over global diets, support a global
standards approach. At the same time, diet and nutrition
are more complex and nuanced than tobacco. Law is an
important global process, but not the only one. The devel-
opment of legal standards in key areas could strengthen a
wider strategy on non-communicable diseases comprising
legal and policy elements, with careful use of partnerships
and economic incentives.
Conclusion
Non-communicable diseases are a serious threat to health
in both developed and developing countries and deserve
to be treated as a global health priority. Enough is known
at the policy level to make a significant impact on the bur-
den of disease. There is a persistent gap, however, between
policy knowledge at the global level, and policy imple-
mentation at country level. This paper has highlighted the
role that global processes can play in generating the polit-
ical commitment to narrow that gap.
The key lifestyle risks for non-communicable diseases
have been clearly identified: tobacco use, physical inactiv-
ity, and the over-consumption of nutrient-poor foods that
contain too much fat, salt, and sugar [21,29]. These factors
cluster together in their impact on key non-communica-
ble diseases [137]. It makes sense, therefore, to link the
FCTC and GSDPAH together as core components of a
broader global strategy on non-communicable diseases.
The implementation of a global strategy on non-commu-
nicable diseases requires intervention in sectors and pol-
icy settings that extend well "beyond the traditional
mandates and authority of health ministries and authori-
ties" [41]. WHO is the obvious agency to coordinate and
act as political champion for a global response. Jointly-
conceived strategies would also be valuable given, for
example, the common interest of WHO and the World
Bank in nutrition and obesity in poor countries. At the
same time, care should be taken with choice of partners so
as not to cede control of issues to agencies whose institu-
tional focus could weaken global health norms. The
potential for WHO to leverage its strategy by using its law-
making powers deserves fresh consideration. Interna-
tional legal standards are not self-executing, and develop-
ing countries require the capacity to implement and
enforce them. However, legal standards also have a nor-
mative role, compliance can be monitored by NGOs as
well as governments, and a global approach could reduce
the health inequalities that might otherwise result from
uneven patterns of "negotiated commitments" with the
processed food industry.
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